Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1986 Oct;22(4):401–408. doi: 10.1111/j.1365-2125.1986.tb02909.x

The effect of glucose on acetylation status.

D Suhardjono, J Boutagy, G M Shenfield
PMCID: PMC1401158  PMID: 3768255

Abstract

Forty-nine healthy volunteers (47 male, 2 female) had their sulphadimidine acetylator status determined on a control day and on a second occasion when they were given an oral glucose load. They were classified as fast and slow acetylators using the standard urine method and as fast, slow and intermediate acetylators using calculated metabolic and total body clearances. Twenty-seven (55%) were slow acetylators and this proportion was not altered by glucose loading either with or before sulphadimidine ingestion. On the control day, five (10%) were fast and 17 (35%) were intermediate acetylators but these sub-groups were not clearly distinguishable from each other when glucose was given. The glucose load did not cause any individual to change from slow to fast categories. Two type 2 (insulin independent) diabetics also showed no difference in acetylator status when studied with widely different blood glucose concentrations. We conclude that glucose can induce minor increases in sulphadimidine clearance but is unlikely to alter phenotypic acetylation status. Previous observations of an increased incidence of fast acetylators in diabetics may therefore indicate a genetic marker.

Full text

PDF
401

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ashby J. P., Deacon A. C., Frier B. M. Glycosylated haemoglobin. Part I: Measurement and clinical interpretation. Diabet Med. 1985 Mar;2(2):83–85. doi: 10.1111/j.1464-5491.1985.tb00605.x. [DOI] [PubMed] [Google Scholar]
  2. Bodansky H. J., Drury P. L., Cudworth A. G., Evans D. A. Acetylator phenotypes and type I (insulin-dependent) diabetics with microvascular disease. Diabetes. 1981 Nov;30(11):907–910. doi: 10.2337/diab.30.11.907. [DOI] [PubMed] [Google Scholar]
  3. Boulton A. J., Worth R. C., Drury J., Hardisty C. A., Wolf E., Cudworth A. G., Ward J. D. Genetic and metabolic studies in diabetic neuropathy. Diabetologia. 1984 Jan;26(1):15–19. doi: 10.1007/BF00252256. [DOI] [PubMed] [Google Scholar]
  4. Burrows A. W., Hockaday T. D., Mann J. I., Taylor J. G. Diabetic dimorphism according to acetylator status. Br Med J. 1978 Jan 28;1(6107):208–210. doi: 10.1136/bmj.1.6107.208. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Chapron C. J., Blum M. R. Relationship of sulfamethazine disposition kinetics to acetylator phenotype in man. A preliminary study. J Clin Pharmacol. 1976 Jul;16(7):338–344. doi: 10.1002/j.1552-4604.1976.tb01530.x. [DOI] [PubMed] [Google Scholar]
  6. Cudworth A. G., Wolf E. The genetic susceptibility to type I (insulin-dependent) diabetes mellitus. Clin Endocrinol Metab. 1982 Jul;11(2):389–408. doi: 10.1016/s0300-595x(82)80021-2. [DOI] [PubMed] [Google Scholar]
  7. Evans D. A. Survey of the human acetylator polymorphism in spontaneous disorders. J Med Genet. 1984 Aug;21(4):243–253. doi: 10.1136/jmg.21.4.243. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Hutchings A., Monie R. D., Spragg B., Routledge P. A. Acetylator phenotyping: the effect of ethanol on the dapsone test. Br J Clin Pharmacol. 1984 Jul;18(1):98–100. doi: 10.1111/j.1365-2125.1984.tb05029.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Ladero J. M., Arrojo A., de Salamanca R. E., Gomez M., Cano F., Alfonso M. Hepatic acetylator phenotype in diabetes mellitus. Ann Clin Res. 1982 Aug;14(4):187–189. [PubMed] [Google Scholar]
  10. Lee E. J., Lee L. K. A simple pharmacokinetic method for separating the three acetylation phenotypes: a preliminary report. Br J Clin Pharmacol. 1982 Mar;13(3):375–378. doi: 10.1111/j.1365-2125.1982.tb01388.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Lunde P. K., Frislid K., Hansteen V. Disease and acetylation polymorphism. Clin Pharmacokinet. 1977 May-Jun;2(3):182–197. doi: 10.2165/00003088-197702030-00003. [DOI] [PubMed] [Google Scholar]
  12. McLaren E. H., Burden A. C., Moorhead P. J. Acetylator phenotype in diabetic neuropathy. Br Med J. 1977 Jul 30;2(6082):291–293. doi: 10.1136/bmj.2.6082.291. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Olsen H., Mørland J. Ethanol-induced increase in drug acetylation in man and isolated rat liver cells. Br Med J. 1978 Nov 4;2(6147):1260–1262. doi: 10.1136/bmj.2.6147.1260. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Olsen H., Mørland J. Ethanol-induced increase in procainamide acetylation in man. Br J Clin Pharmacol. 1982 Feb;13(2):203–208. doi: 10.1111/j.1365-2125.1982.tb01357.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Pontiroli A. E., Mosca A., de Pasqua A., Alcini D., Pozza G. The fast acetylator phenotype in diabetes mellitus: abnormal prevalence and association with the ABO blood groups. Diabetologia. 1984 Aug;27(2):235–237. doi: 10.1007/BF00273812. [DOI] [PubMed] [Google Scholar]
  16. Schröder H. Simplified method for determining acetylator phenotype. Br Med J. 1972 Aug 26;3(5825):506–507. doi: 10.1136/bmj.3.5825.506. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Shenfield G. M., McCann V. J., Tjokresetio R. Acetylator status and diabetic neuropathy. Diabetologia. 1982 Jun;22(6):441–444. doi: 10.1007/BF00282587. [DOI] [PubMed] [Google Scholar]
  18. Weber W. W., Hein D. W. N-acetylation pharmacogenetics. Pharmacol Rev. 1985 Mar;37(1):25–79. [PubMed] [Google Scholar]
  19. du Souich P., McLean A. J., Stoeckel K., Ohlendorf D., Gibaldi M. Screening methods using sulfamethazine for determining acetylator phenotype. Clin Pharmacol Ther. 1979 Dec;26(6):757–765. doi: 10.1002/cpt1979266757. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES